{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T10:21:13Z","timestamp":1791195673978,"version":"4.1.0"},"reference-count":93,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2017,3,21]],"date-time":"2017-03-21T00:00:00Z","timestamp":1490054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"name":"General Clinical Research Centers","award":["MO1-RR00109"],"award-info":[{"award-number":["MO1-RR00109"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle Nerve"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1002\/mus.25597","type":"journal-article","created":{"date-parts":[[2017,2,6]],"date-time":"2017-02-06T03:16:46Z","timestamp":1486351006000},"page":"185-196","source":"Crossref","is-referenced-by-count":258,"title":["Rituximab treatment of myasthenia gravis: A systematic review"],"prefix":"10.1002","volume":"56","author":[{"given":"Rup","family":"Tandan","sequence":"first","affiliation":[{"name":"Department of Neurological Sciences; University of Vermont, Robert Larner College of Medicine and University of Vermont Medical Center; Room 426, Health Sciences Research Facility, 149 Beaumont Avenue Burlington Vermont 05405 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Michael K.","family":"Hehir","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences; University of Vermont, Robert Larner College of Medicine and University of Vermont Medical Center; Room 426, Health Sciences Research Facility, 149 Beaumont Avenue Burlington Vermont 05405 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqar","family":"Waheed","sequence":"additional","affiliation":[{"name":"Department of Neurological Sciences; University of Vermont, Robert Larner College of Medicine and University of Vermont Medical Center; Room 426, Health Sciences Research Facility, 149 Beaumont Avenue Burlington Vermont 05405 USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diantha B.","family":"Howard","sequence":"additional","affiliation":[{"name":"Center for Clinical and Translational Science; University of Vermont, Robert Larner College of Medicine and University of Vermont Medical Center; Burlington Vermont USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,21]]},"reference":[{"key":"10.1002\/mus.25597-BIB0001|mus25597-cit-0001","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s13311-015-0398-y","article-title":"Current treatment, emerging translational therapies, and new therapeutic targets for autoimmune myasthenia gravis","volume":"13","author":"Guptill","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1002\/mus.25597-BIB0002|mus25597-cit-0002","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1586\/eci.12.34","article-title":"Muscle antibodies in myasthenia gravis: beyond diagnosis?","volume":"8","author":"Meriggioli","year":"2012","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1002\/mus.25597-BIB0003|mus25597-cit-0003","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1002\/mus.25597-BIB0004|mus25597-cit-0004","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat Med"},{"key":"10.1002\/mus.25597-BIB0005|mus25597-cit-0005","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0006|mus25597-cit-0006","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIG and PLEX inpatients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0007|mus25597-cit-0007","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/jamaneurol.2014.17","article-title":"Comparison of plasmapheresis and intravenous immunoglobulin as maintenance therapies for juvenile myasthenia gravis","volume":"71","author":"Liew","year":"2014","journal-title":"JAMA Neurol"},{"key":"10.1002\/mus.25597-BIB0008|mus25597-cit-0008","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1602489","article-title":"Randomized trial of thymectomy in myasthenia gravis","volume":"375","author":"Wolfe","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1002\/mus.25597-BIB0009|mus25597-cit-0009","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jns.2016.08.057","article-title":"Maintenance immunosuppression in myasthenia gravis","volume":"369","author":"Gotterer","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1002\/mus.25597-BIB0010|mus25597-cit-0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1002\/mus.25597-BIB0011|mus25597-cit-0011","first-page":"255","article-title":"Clinical characteristics of refractory myasthenia gravis patients","volume":"86","author":"Suh","year":"2013","journal-title":"Yale J Biol Med"},{"key":"10.1002\/mus.25597-BIB0012|mus25597-cit-0012","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1002\/mus.25597-BIB0013|mus25597-cit-0013","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/cts.12111","article-title":"Rituximab for non-Hodgkin's lymphoma: a story of rapid success in translation","volume":"7","author":"Harrison","year":"2014","journal-title":"Clin Trans Sci"},{"key":"10.1002\/mus.25597-BIB0014|mus25597-cit-0014","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1002\/mus.25597-BIB0015|mus25597-cit-0015","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1002\/mus.25597-BIB0016|mus25597-cit-0016","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1213277","article-title":"Efficacy of remission-induction regimens for ANCA-associated vasculitis","volume":"369","author":"Specks","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1002\/mus.25597-BIB0017|mus25597-cit-0017","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s12185-015-1887-9","article-title":"Efficacy and safety of rituximab in Japanese patients with relapsed chronic immune thrombocytopenia refractory to conventional therapy","volume":"102","author":"Miyakawa","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1002\/mus.25597-BIB0018|mus25597-cit-0018","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1182\/blood-2015-01-588392","article-title":"The role of rituximab in adults with warm antibody autoimmune hemolytic anemia","volume":"125","author":"Dierickx","year":"2015","journal-title":"Blood"},{"key":"10.1002\/mus.25597-BIB0019|mus25597-cit-0019","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMoa0904452","article-title":"Rituximab, B-lymphocyte depletion, and preservation of beta-cell function","volume":"361","author":"Pescovitz","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1002\/mus.25597-BIB0020|mus25597-cit-0020","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"key":"10.1002\/mus.25597-BIB0021|mus25597-cit-0021","doi-asserted-by":"crossref","first-page":"928","DOI":"10.2340\/00015555-2116","article-title":"Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens","volume":"95","author":"Wang","year":"2015","journal-title":"Acta Derm Venereol"},{"key":"10.1002\/mus.25597-BIB0022|mus25597-cit-0022","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s13311-015-0402-6","article-title":"Anti-B-cell therapies in autoimmune neurological diseases: rationale and efficacy trials","volume":"13","author":"Alexopoulos","year":"2016","journal-title":"Neurotherapeutics"},{"key":"10.1002\/mus.25597-BIB0023|mus25597-cit-0023","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis. Recommendations for clinical research standards: Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America","volume":"55","author":"Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0024|mus25597-cit-0024","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann NY Acad Sci"},{"key":"10.1002\/mus.25597-BIB0025|mus25597-cit-0025","volume-title":"Applied logistic regression","year":"1989"},{"key":"10.1002\/mus.25597-BIB0026|mus25597-cit-0026","volume-title":"Practical nonparametric statistics","year":"1971"},{"key":"10.1002\/mus.25597-BIB0027|mus25597-cit-0027","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.55.7.1062-a","article-title":"Rituximab for myasthenia gravis developing after bone marrow transplant","volume":"55","author":"Zaja","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0028|mus25597-cit-0028","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1067\/S0022-3476(03)00300-7","article-title":"Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report","volume":"143","author":"Wylam","year":"2003","journal-title":"J Pediatr"},{"key":"10.1002\/mus.25597-BIB0029|mus25597-cit-0029","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/ajh.20169","article-title":"Response of myasthenis gravis to rituximab in a patient with non-Hodgkin lymphoma","volume":"77","author":"Gajra","year":"2004","journal-title":"Am J Hematol"},{"key":"10.1002\/mus.25597-BIB0030|mus25597-cit-0030","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1007\/s00277-005-1050-4","article-title":"Anti-CD20 antibody (rituximab) therapy in a myasthenia gravis patient with follicular lymphoma","volume":"84","author":"Takagi","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1002\/mus.25597-BIB0031|mus25597-cit-0031","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mus.20411","article-title":"High-dose cyclophosphamide in refractory myasthenia gravis with MuSK antibodies","volume":"33","author":"Lin","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0032|mus25597-cit-0032","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/mus.20479","article-title":"Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab","volume":"33","author":"Hain","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0033|mus25597-cit-0033","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1136\/jnnp.2006.093567","article-title":"Complete remission induced by rituximab in refractory seronegative, muscle-specific, kinase-positive myasthenia gravis","volume":"78","author":"Baek","year":"2007","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mus.25597-BIB0034|mus25597-cit-0034","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1007\/s00415-006-0442-2","article-title":"Rituximab in refractory MuSK antibody myasthenia gravis","volume":"254","author":"Thakre","year":"2007","journal-title":"J Neurol"},{"key":"10.1002\/mus.25597-BIB0035|mus25597-cit-0035","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1007\/s00415-007-0593-9","article-title":"Rescue therapy with anti-CD20 treatment in neuroimmunologic breakthrough disease","volume":"254","author":"Chan","year":"2007","journal-title":"J Neurol"},{"key":"10.1002\/mus.25597-BIB0036|mus25597-cit-0036","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ncpneuro0526","article-title":"Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome","volume":"3","author":"Diaz-Manera","year":"2007","journal-title":"Nat Clin Prac Neurol"},{"key":"10.1002\/mus.25597-BIB0037|mus25597-cit-0037","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ncponc1071","article-title":"Methotrexate-associated mantle-cell lymphoma in an elderly man with myasthenia gravis","volume":"5","author":"Tran","year":"2007","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1002\/mus.25597-BIB0038|mus25597-cit-0038","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann NY Acad Sci"},{"key":"10.1002\/mus.25597-BIB0039|mus25597-cit-0039","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mus.21047","article-title":"Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis","volume":"38","author":"Kerkani","year":"2008","journal-title":"Muscle Nerve"},{"issue":"suppl 1","key":"10.1002\/mus.25597-BIB0040|mus25597-cit-0040","first-page":"A302","article-title":"Intractable myasthenia gravis responding to rituximab treatment","volume":"70","author":"Gardner","year":"2009","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0041|mus25597-cit-0041","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/archneurol.2009.28","article-title":"Allogeneic hematopoietic cell transplantation for refractory myasthenia gravis","volume":"66","author":"Strober","year":"2009","journal-title":"Arch Neurol"},{"key":"10.1002\/mus.25597-BIB0042|mus25597-cit-0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4076\/1757-1626-2-6609","article-title":"Rituximab for the treatment of refractory pediatric autoimmune diseases: a case series","volume":"2","author":"Tzaribachev","year":"2009","journal-title":"Cases J"},{"key":"10.1002\/mus.25597-BIB0043|mus25597-cit-0043","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1007\/s12185-010-0503-2","article-title":"Myasthenia gravis developing in a patient with CNS lymphoma","volume":"91","author":"Masroujeh","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1002\/mus.25597-BIB0044|mus25597-cit-0044","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1212\/WNL.0b013e31820d6290","article-title":"Rituximab is successful in an HIV-positive patient with MuSK myasthenia gravis","volume":"76","author":"Kuntzer","year":"2011","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0045|mus25597-cit-0045","first-page":"77","article-title":"Refractory bulbar and respiratory dysfunction in a young Chinese woman with seronegative, muscle-specific tyrosine kinase antibody-positive myasthenia gravis: response to cyclophosphamide and rituximab treatment","volume":"17","author":"Lau","year":"2011","journal-title":"Hong Kong Med J"},{"key":"10.1002\/mus.25597-BIB0046|mus25597-cit-0046","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.pediatrneurol.2012.05.017","article-title":"Rituximab in severe seronegative juvenile myasthenia gravis: review of the literature","volume":"47","author":"Koul","year":"2012","journal-title":"Pediatr Neurol"},{"key":"10.1002\/mus.25597-BIB0047|mus25597-cit-0047","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/mus.23311","article-title":"Rituximab therapy for Morvan syndrome associated with myasthenia gravis","volume":"46","author":"Weiss","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0048|mus25597-cit-0048","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.nmd.2013.03.014","article-title":"Myocardial infarction after rituximab infusion","volume":"23","author":"Renard","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1002\/mus.25597-BIB0049|mus25597-cit-0049","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/mus.23657","article-title":"Myasthenia gravis, Castleman disease, pemphigus, and anti-phospholipid syndrome","volume":"47","author":"Jakubikova","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0050|mus25597-cit-0050","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/mus.24063","article-title":"Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment","volume":"48","author":"Yi","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0051|mus25597-cit-0051","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/pbc.24799","article-title":"Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab","volume":"61","author":"Unal","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/mus.25597-BIB0052|mus25597-cit-0052","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaophthalmol.2014.16","article-title":"Systemic inflammatory pseudotumor and myasthenia gravis","volume":"132","author":"Levin","year":"2014","journal-title":"JAMA Ophthalmol"},{"key":"10.1002\/mus.25597-BIB0053|mus25597-cit-0053","doi-asserted-by":"crossref","first-page":"227","DOI":"10.5692\/clinicalneurol.55.227","article-title":"A case of refractory generalized myasthenia gravis with anti-acetylcholine receptor antibodies treated with rituximab","volume":"55","author":"Hayashi","year":"2015","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1002\/mus.25597-BIB0054|mus25597-cit-0054","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.nmd.2015.03.014","article-title":"Selective response to rituximab in a young child with MuSK-associated myasthenia gravis","volume":"25","author":"Govindarajan","year":"2015","journal-title":"Neuromuscul Disord"},{"key":"10.1002\/mus.25597-BIB0055|mus25597-cit-0055","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jneuroim.2008.04.039","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients","volume":"201-202","author":"Illa","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1002\/mus.25597-BIB0056|mus25597-cit-0056","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1468-1331.2008.02399.x","article-title":"Successful treatment of refractory generalized myasthenia gravis with rituximab","volume":"16","author":"Lebrun","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1002\/mus.25597-BIB0057|mus25597-cit-0057","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CND.0b013e31819a8403","article-title":"Rituximab for the treatment of thymoma-associated and de novo myasthenia gravis: 3 cases and review","volume":"10","author":"Nelson","year":"2009","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1002\/mus.25597-BIB0058|mus25597-cit-0058","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2009.02.357","article-title":"Rituximab for myasthenia gravis. Three case reports and review of the literature","volume":"280","author":"Steiglbauer","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1002\/mus.25597-BIB0059|mus25597-cit-0059","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/mus.21521","article-title":"Rituximab in the management of refractory myasthenia gravis","volume":"41","author":"Zebardast","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0060|mus25597-cit-0060","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1600-0404.2010.01345.x","article-title":"Rituximab for severe myasthenia gravis-experience from five patients","volume":"122","author":"Lindberg","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1002\/mus.25597-BIB0061|mus25597-cit-0061","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/WCO.0b013e32833c0982","article-title":"Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis","volume":"23","author":"Guptill","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"10.1002\/mus.25597-BIB0062|mus25597-cit-0062","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CND.0b013e3181fcc109","article-title":"Prolonged improvement after rituximab: two cases of resistant muscle-specific receptor tyrosine kinase\u2009+\u2009myasthenia gravis","volume":"12","author":"Burusnukul","year":"2010","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1002\/mus.25597-BIB0063|mus25597-cit-0063","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1002\/mus.25597-BIB0064|mus25597-cit-0064","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/CND.0b013e3181df2b3e","article-title":"Rituximab in the treatment of MuSK antibody-positive myasthenia gravis","volume":"12","author":"Stein","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1002\/mus.25597-BIB0065|mus25597-cit-0065","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/1756285611411503","article-title":"Response of patients with refractory myasthenia gravis to rituximab: a retrospective study","volume":"4","author":"Nowak","year":"2011","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1002\/mus.25597-BIB0066|mus25597-cit-0066","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jnnp.2010.220475","article-title":"Use and monitoring of low dose rituximab in myasthenia gravis","volume":"82","author":"Blum","year":"2011","journal-title":"J Neurol Neurosurgery Psychiatry"},{"key":"10.1002\/mus.25597-BIB0067|mus25597-cit-0067","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1136\/jnnp.2009.174888","article-title":"Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis","volume":"82","author":"Sadnicka","year":"2011","journal-title":"J Neurol Neurosurgery Psychiatry"},{"key":"10.1002\/mus.25597-BIB0068|mus25597-cit-0068","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/10428194.2011.615426","article-title":"Myasthenia gravis, an autoimmune manifestation of lymphoma and lymphoproliferative disorders: case reports and review of the literature","volume":"53","author":"Rezania","year":"2012","journal-title":"Leukemia Lymphoma"},{"key":"10.1002\/mus.25597-BIB0069|mus25597-cit-0069","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"Diaz-Manera","year":"2012","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0070|mus25597-cit-0070","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/mus.23412","article-title":"Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study","volume":"46","author":"Collongues","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0071|mus25597-cit-0071","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1007\/s00415-013-6987-y","article-title":"Changes in regulatory T cells after rituximab in two patients with refractory myasthenia gravis","volume":"260","author":"Catzola","year":"2013","journal-title":"J Neurol"},{"key":"10.1002\/mus.25597-BIB0072|mus25597-cit-0072","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1136\/jnnp-2012-303664","article-title":"Long-term benefit of rituximab in MuSK autoantibody myasthenia gravis patients","volume":"84","author":"Keung","year":"2013","journal-title":"J Neurol Neurosurgery Psychiatry"},{"key":"10.1002\/mus.25597-BIB0073|mus25597-cit-0073","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.23951","article-title":"Interleukin-10-producing B cells and their association with responsiveness to rituximab in myasthenia gravis","volume":"49","author":"Sun","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0074|mus25597-cit-0074","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acethylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1002\/mus.25597-BIB0075|mus25597-cit-0075","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.23944","article-title":"Does change in acetylcholine receptor antibody level correlate with clinical change in myasthenia gravis?","volume":"49","author":"Sanders","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0076|mus25597-cit-0076","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0077|mus25597-cit-0077","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1212\/NXI.0000000000000077","article-title":"Characterization of B cells in muscle specific tyrosine kinase antibody myasthenia gravis","volume":"2","author":"Guptill","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1002\/mus.25597-BIB0078|mus25597-cit-0078","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.critrevonc.2006.09.004","article-title":"Pharmacokinetics of rituximab and its clinical use: thought for the best use?","volume":"1","author":"Cartron","year":"2007","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1002\/mus.25597-BIB0079|mus25597-cit-0079","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","article-title":"Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma","volume":"9","author":"Berinstein","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1002\/mus.25597-BIB0080|mus25597-cit-0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007691-200006000-00010","article-title":"Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study","volume":"3","author":"Iacona","year":"2000","journal-title":"Ther Drug Monit"},{"key":"10.1002\/mus.25597-BIB0081|mus25597-cit-0081","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/j.1538-7836.2010.03818.x","article-title":"Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura","volume":"8","author":"McDonald","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1002\/mus.25597-BIB0082|mus25597-cit-0082","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","article-title":"Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings","volume":"27","author":"Regazzi","year":"2005","journal-title":"Ther Drug Monit"},{"key":"10.1002\/mus.25597-BIB0083|mus25597-cit-0083","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/ard.2008.091124","article-title":"Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases","volume":"67","author":"Lu","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/mus.25597-BIB0084|mus25597-cit-0084","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/mus.25597-BIB0085|mus25597-cit-0085","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/mus.24063","article-title":"Prolonged B-cell depletion in MuSK myasthenia gravis following rituximab treatment","volume":"48","author":"Yi","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1002\/mus.25597-BIB0086|mus25597-cit-0086","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1002\/mus.25597-BIB0087|mus25597-cit-0087","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An International, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0088|mus25597-cit-0088","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","author":"Muscle Study Group","year":"2008","journal-title":"Neurology"},{"key":"10.1002\/mus.25597-BIB0089|mus25597-cit-0089","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1002\/mus.25597-BIB0090|mus25597-cit-0090","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1002\/mus.25597-BIB0091|mus25597-cit-0091","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cpt.207","article-title":"Drug-induced progressive multifocal leukoencephalopathy: lessons learned from contrasting natalizumab and rituximab","volume":"98","author":"Vermeer","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/mus.25597-BIB0092|mus25597-cit-0092","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1212\/CPJ.0000000000000202","article-title":"PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents","author":"Kanth","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"10.1002\/mus.25597-BIB0093|mus25597-cit-0093","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s40263-014-0168-0","article-title":"Natalizumab: risk stratification of individual patients","volume":"28","author":"Tur","year":"2014","journal-title":"CNS Drugs"}],"container-title":["Muscle & Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.25597","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/mus.25597","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:44:17Z","timestamp":1625445857000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.25597"}},"subtitle":["Rituximab in Myasthenia Gravis"],"short-title":[],"issued":{"date-parts":[[2017,3,21]]},"references-count":93,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,8]]}},"URL":"https:\/\/doi.org\/10.1002\/mus.25597","archive":["Portico"],"relation":{},"ISSN":["0148-639X"],"issn-type":[{"value":"0148-639X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3,21]]}}}